



PIPER MARBURY
RUDNICK & WOLFE^{LLP}
1200 NINETEENTH STREET, NW
WASHINGTON, DC 20036-2412
TELEPHONE: 202-861-3900
FACSIMILE: 202-223-2085

RECEIVED
APR 19 2001
TECH CENTER 1600/2900

DOCKET NO.: 9491-043-27 DIV

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

Re: Serial No.: 09/610,152
Applicant(s): NAPOLEONE FERRARA, ET AL.
Filing Date: JULY 5, 2000
For: IMPROVED ANGIOGENESIS USING HEPATOCYTE GROWTH
FACTOR
Group Art Unit: 1651
Examiner: WEBER J.

SIR:

Attached hereto for filing are the following papers:

RESPONSE TO RESTRICTION REQUIREMENT

Our check in the amount of \$-0- is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary extension of time to make the filing of the attached documents timely, please charge or credit the difference to Deposit Account No. 50-1442. Further, if these papers are not considered timely filed, then a request is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

PIPER MARBURY RUDNICK & WOLFE LLP

Steven B. Kelber
Attorney of Record
Registration No.: 30,073


Amy L. Miller
Registration No.: 43,804

04-18-01

Date

RECEIVED

APR 19 2001



Docket No. 9491-043-27 DIV

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: NAPOLEONE FERRARA, ET AL.

GAU: 1651

SERIAL NO: 09/610,152

EXAMINER: WEBER, J.

FILING DATE: JULY 5, 2000

FOR: IMPROVED ANGIOGENESIS USING HEPATOCYTE GROWTH FACTOR

#5
P.83
4/24/01

RESPONSE TO RESTRICTION REQUIREMENT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Responsive to the Restriction Requirement dated March 28, 2001, Applicants elect, albeit with traverse, Group I, Claims 8-13 for further prosecution at this time.

REMARKS

The Examiner has required restriction in the above-identified application as follows:

Group I, Claims 8-13, drawn to a kit and a pharmaceutical composition comprising HGF, classified in class 530, subclass 399; and

Group II, Claims 14-15, drawn to a pharmaceutical composition comprising HGF and VEGF, classified in class 530, subclass 399.

Thus, the 8 claims pending in this application have been separated into two separate groups. Applicants elect, with traverse Group I, Claims 8-13 for examination purposes only.

Applicants respectfully traverse, on the grounds that the claims are to a certain extent coextensive, and if not coextensive, interrelated so as to require examination in a single